Učitavanje...

Afatinib in advanced pretreated non-small-cell lung cancer— a Canadian experience

BACKGROUND: Afatinib, an irreversible epidermal growth factor receptor tyrosine kinase inhibitor (egfr tki), is approved for first-line therapy in advanced EGFR mutation–positive non-small-cell lung cancer (nsclc) and has previously demonstrated activity after failure of chemotherapy and reversible...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Curr Oncol
Glavni autori: Ezeife, D.A., Melosky, B., Tudor, R., Lin, S., Lau, A., Panzarella, T., Leighl, N.B.
Format: Artigo
Jezik:Inglês
Izdano: Multimed Inc. 2018
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6209553/
https://ncbi.nlm.nih.gov/pubmed/30464688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.25.3914
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!